Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.62 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR1E | P28566 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2166733 | 0.98 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3PYCR1SIGMAR1 | |
| Propene SCHEMBL2169931 | 0.89 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3PYCR1SIGMAR1 | |
| SCHEMBL7079099 | 0.83 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3PYCR1SIGMAR1 | |
| SCHEMBL19576554 | 0.83 | PYCR1 (0.56) | SLC6A2SLC6A4SLC6A3PYCR1SIGMAR1 | |
| SCHEMBL18901128 | 0.83 | PYCR1 (0.56) | SLC6A2SLC6A4SLC6A3PYCR1SIGMAR1 | |
| SCHEMBL23992712 | 0.81 | HTR1A (0.47) | SLC6A2SLC6A4SLC6A3PYCR1SIGMAR1 | |
| SCHEMBL13478300 | 0.81 | HTR2A (0.47) | SLC6A2SLC6A4SLC6A3PYCR1SIGMAR1 | |
| SCHEMBL15051655 | 0.81 | HTR7 (0.47) | SLC6A2SLC6A4SLC6A3PYCR1SIGMAR1 | |
| SCHEMBL23357811 | 0.81 | HRH3 (0.45) | SLC6A2SLC6A4SLC6A3PYCR1SIGMAR1 | |
| SCHEMBL8290709 | 0.81 | TAAR1 (0.47) | SLC6A2SLC6A4SLC6A3PYCR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0041448-A1 | Disinfecting composition containing a quaternary ammonium and an oligomer of hexamethylene-diguanide hydrochloride | Salkin, Nicolas (FR) | 1981-12-09 | — | — | EP | claimed |
| US-20250024837-A1 | PESTICIDE SYSTEM | BANISH, MICHELE | 2025-01-23 | — | — | US | disclosed |
| EP-3538529-B1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-KB PATHWAYS | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT (DE) | 2022-01-19 | — | — | EP | disclosed |
| US-11028084-B2 | Selective inhibitors of gentotoxic steress-induced IKK/NF-κB pathways | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2021-06-08 | — | — | US | disclosed |
| US-11014912-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| EP-3519385-B1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2020-11-18 | — | — | EP | disclosed |
| US-20190276452-A1 | SELECTIVE INHIBITORS OF GENTOTOXIC STERESS-INDUCED IKK/NF-KB PATHWAYS | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2019-09-12 | — | — | US | disclosed |
| EP-3321264-A1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-KB PATHWAYS | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2018-05-16 | — | — | EP | disclosed |
| WO-2018060689-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-05 | — | — | WO | disclosed |
| US-20170319536-A1 | Arginase Inhibitors and Their Therapeutic Applications | Oncoarendi Therapeutics S.A. (PL) | 2017-11-09 | — | — | US | disclosed |
| CN-105315160-A | Benzyl tertiary amine, preparation method and applications thereof | UNIV ZHEJIANG OCEAN | 2016-02-10 | — | — | CN | disclosed |
| EP-1553955-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PROINFLAMMATORY CYTOKINES | COMBINATORX INC (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008118423-A1 | COMPOSITIONS AND METHODS FOR TREATING MEDICAL CONDITIONS | COMBINATORX, INCORPORATED (US) | 2008-10-02 | — | — | WO | disclosed |
| EP-1599212-A4 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1599212-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2005079284-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PROINFLAMMATORY CYTOKINES | COMBINATORX, INCORPORATED (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-1553955-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PROINFLAMMATORY CYTOKINES | Combinatorx, Incorporated (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004030618-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PROINFLAMMATORY CYTOKINES | COMBINATORX, INCORPORATED (US) | 2004-04-15 | — | — | WO | disclosed |
| EP-0041448-A1 | Disinfecting composition containing a quaternary ammonium and an oligomer of hexamethylene-diguanide hydrochloride | Salkin, Nicolas (FR) | 1981-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014912-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | USP30, USP39, USP28 | SLC6A2 4696/4885SLC6A4 4647/4885SLC6A3 4618/4885 |
| US-11028084-B2 | Selective inhibitors of gentotoxic steress-induced IKK/NF-κB pathways | IKBKB, NFKBIA, IKBKE | SLC6A2 3018/4885SLC6A4 3177/4885SLC6A3 3376/4885 |
| US-20190276452-A1 | SELECTIVE INHIBITORS OF GENTOTOXIC STERESS-INDUCED IKK/NF-KB PATHWAYS | IKBKB, NFKBIA, IKBKE | SLC6A2 3019/4885SLC6A4 3227/4885SLC6A3 3409/4885 |
| US-20250024837-A1 | PESTICIDE SYSTEM | ACHE, PFAS, FPGS | SLC6A2 4774/4885SLC6A4 4377/4885SLC6A3 4590/4885 |
| US-20170319536-A1 | Arginase Inhibitors and Their Therapeutic Applications | ARG1, ARG2, ARGLU1 | SLC6A2 2942/4885SLC6A4 4411/4885SLC6A3 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.